Health
J&J COVID-19 vaccine is 72% effective in the U.S., and 66% overall in large trial – Reuters
Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants which will…
(Reuters) – Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants which will give health officials another weapon to tackle the coronavirus.
FILE PHOTO: A vial and sryinge are seen in front of a displayed Johnson&Johnson logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from…
-
Noosa News5 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News6 hours agoMotorcyclist dies in crash with truck
-
Noosa News20 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General20 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate